))
S3 E2 - Marina Baretti, MD – Management of Safety When Using FGFR inhibitors
Manage episode 407348221 series 3559566
Innhold levert av Karger Publishers. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Karger Publishers eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
This is the second episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Dr. Marina Baretti discusses the safety of fibroblast growth factor receptor (FGFR) inhibitors, drawing from her clinical experience. She details current safety data, and explains what you need to know about the management of their side effects and adverse events.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.
17 episoder
Del
